Inhaled therapy can only work when medicine reaches where it needs to go, at the moment it needs to get there.
But too often, treatment depends on the patient doing everything right. Breathe at the right time. Use the device correctly. Tolerate the sensation. Complete the dose. Repeat the process consistently, even when breathing is already compromised.
For children, elderly patients, people with COPD, neurodiverse patients and those with low lung function, that is a lot to ask.
MISTI® exists because inhaled therapy should not ask vulnerable patients to work harder than the device.
Using mesh free aerosol generation, breath actuated delivery and connected treatment visibility, MISTI® is being developed to close the gap between what medicine can do and what patients can reliably receive.
Respiratory care is changing. Biologics, RNA based therapies, gene therapies and other advanced formulations are opening new possibilities for treatment.
But these medicines can place new demands on delivery.
The delivery system can no longer be an afterthought.
MISTI’s mesh free acoustic delivery approach is being developed for this shift, supporting a more controlled pulmonary drug delivery pathway for today’s respiratory needs and tomorrow’s advanced inhaled therapies.
MISTI® is designed around a simple belief: delivery should respond to the patient, not the other way around.
Breath actuation helps align
aerosol delivery with inhalation.
Mesh free acoustic aerosol generation removes reliance on a traditional mesh.
Connected treatment visibility may help show how, when and whether delivery happened.
It is not only focused on what is delivered - it is built to transform how things are delivered.
MISTI brings together technical precision and patient centred design to support more reliable pulmonary delivery.
Less dependence on perfect technique
Breath actuated delivery helps reduce reliance on patient coordination, timing and breathing strength.
Delivery timed to the breath
Medicine is released in response to inhalation, helping align delivery with the moment it can matter most.
Visibility where care is usually hidden
Connected use data may help clinicians and caregivers understand whether treatment was activated, completed and delivered in line with the patient’s breathing pattern.
Designed around patients who need support most
The wearable format is being developed for people who may struggle with traditional inhalers, spacers or nebulisers.
Built for therapies that need better delivery
MISTI’s mesh free pulmonary drug delivery approach is being developed with potential relevance across respiratory medicines, biologics, RNA based therapies and future inhaled therapeutic classes.
The advantage is not one feature. It is the way the system is designed around the reality of delivery.
MISTI brings together technical precision and patient centred design to support more reliable pulmonary delivery.
Less dependence on perfect technique
Breath actuated delivery helps reduce reliance on patient coordination, timing and breathing strength.
Delivery timed to the breath
Medicine is released in response to inhalation, helping align delivery with the moment it can matter most.
Visibility where care is usually hidden
Connected use data may help clinicians and caregivers understand whether treatment was activated, completed and delivered in line with the patient’s breathing pattern.
Designed around patients who need support most
The wearable format is being developed for people who may struggle with traditional inhalers, spacers or nebulisers.
Built for therapies that need better delivery
MISTI’s mesh free pulmonary drug delivery approach is being developed with potential relevance across respiratory medicines, biologics, RNA based therapies and future inhaled therapeutic classes.
The advantage is not one feature. It is the way the system is designed around the reality of delivery.
MISTI brings together technical precision and patient centred design to support more reliable pulmonary delivery.
Less dependence on perfect technique
Breath actuated delivery helps reduce reliance on patient coordination, timing and breathing strength.
Delivery timed to the breath
Medicine is released in response to inhalation, helping align delivery with the moment it can matter most.
Visibility where care is usually hidden
Connected use data may help clinicians and caregivers understand whether treatment was activated, completed and delivered in line with the patient’s breathing pattern.
Designed around patients who need support most
The wearable format is being developed for people who may struggle with traditional inhalers, spacers or nebulisers.
Built for therapies that need better delivery
MISTI’s mesh free pulmonary drug delivery approach is being developed with potential relevance across respiratory medicines, biologics, RNA based therapies and future inhaled therapeutic classes.
The advantage is not one feature. It is the way the system is designed around the reality of delivery.
MedMISTI™ is the first real world application of the technology, but the broader opportunity
is larger.
MISTI’s platform is being developed around delivery principles that can apply across
multiple pathways: controlled aerosol generation, breath synchronised delivery, particle
size control, connected visibility and patient centred usability.
That means MISTI® can begin with respiratory care and expand towards future applications
where pulmonary delivery may offer strategic value.
For patients, this may mean easier and more consistent inhaled therapy. For clinicians, it
may mean greater visibility over treatment use. For pharmaceutical partners, it may offer a
pathway for advanced inhaled therapies.
MISTI® is not just building a device.
It is building a new way to think about delivery through the lungs.
MISTI® began with the lived reality of respiratory care: when breathing becomes fragile, treatment needs to feel simple, reliable and within reach.
MedMISTI™ gives the platform a focused starting point: respiratory care patients whose treatment success depends on usability, timing and consistency.
That includes children who may fear or resist traditional treatment devices. Elderly patients who may struggle with coordination or cognition. People living with asthma or COPD. Neurodiverse patients with sensory needs. Caregivers who need more confidence that treatment was completed. Clinicians who need better visibility over what is happening outside the clinic.
This is where the “why” becomes practical.
MISTI® is not only asking how medicine can be aerosolised. It is asking how inhaled therapy can become easier to complete, easier to monitor and better aligned to real patient behaviour.
A partner does not engage with MISTI® because the mission is meaningful alone.
They engage because the delivery problem is urgent, the technology is differentiated and the timing matters.
Therapies are becoming more complex. Care is moving beyond hospital settings. Health systems and visibility. Pharmaceutical teams need delivery pathways that can support formulation integrity, patient usability and future commercial potential. Current devices can leave too much uncertainty at the point of delivery.
MISTI® offers a different pathway: mesh free, breath actuated and built around the moment medicine needs to move through the lungs.
For pharmaceutical, healthcare and strategic partners, that creates an opportunity to engage before pulmonary drug delivery becomes one of the defining infrastructure challenges of next generation medicine.
Medicine can only do its job when it reaches the body in the right way.
MISTI® exists to help make that possible through the lungs, with a mesh free pulmonary
delivery platform designed for greater control, consistency and visibility.
The first application is respiratory care.
The broader ambition is a future where advanced therapies can be delivered more accessibly, more
intelligently and with more confidence.
Find answers about how MedMISTI™ works and what it can do for you
Inhaled therapy can fail when medicine does not reach the lungs consistently. This may happen because of poor timing, incorrect device technique, low breathing strength, poor tolerance, inconsistent particle size, device limitations or incomplete treatment use.
The lungs offer a direct pathway for respiratory treatment and a potential non invasive route for advanced therapies. MISTI® is focused on pulmonary drug delivery because better delivery through the lungs may improve treatment reliability today and open new pathways for future medicines.
Breath actuated delivery helps align medicine release with the patient’s inhalation. This can reduce reliance on perfect patient timing and may support more consistent treatment delivery, especially for patients who struggle with traditional inhalers, spacers or nebulisers.
Mesh based systems can face limitations when drug flow is restricted, particles vary or formulations are not suited to the device. MISTI’s mesh free approach uses high frequency acoustic energy to generate aerosol without relying on a traditional mesh, supporting a more adaptable pulmonary delivery pathway.
Advanced therapies such as biologics, RNA based medicines and gene therapies can be sensitive to heat, shear force, formulation conditions and delivery method. MISTI® is being developed as a gentler, more controlled pulmonary delivery approach that may support future inhaled therapeutic applications.
MedMISTI™ gives the platform a focused starting point in respiratory care, where treatment success depends heavily on usability, timing, consistency and patient adherence. It allows MISTI® to prove the platform in a real world setting before expanding into broader pulmonary delivery applications.
Respiratory treatment often happens outside the clinic, where clinicians and caregivers cannot easily see whether the dose was taken correctly or completed. Connected visibility may help capture use events, adherence patterns and delivery related data that support better clinical care decisions.
Pharmaceutical partners may engage with MISTI® because advanced inhaled therapies require more controlled and formulation conscious delivery. MISTI® offers a potential pulmonary delivery pathway for medicines that may be difficult to deliver through conventional systems.
Healthcare partners may engage with MISTI® because respiratory care is increasingly moving into home and community settings. A more usable, connected and patient aligned delivery approach could support optimal dose, treatment visibility and earlier intervention.
The timing matters because therapies are becoming more complex, healthcare systems are under pressure, and more care is taking place outside hospital settings. Pulmonary drug delivery needs to become more reliable, more visible and more adaptable to support the next era of medicine.
